author-photo

Richard J. Schwab

University of California, San Diego

4

Papers

5

Citations

Citation Trend

Filter By

Papers (3) Sort By

Journal Conference Others

Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial

2021 Cancer Cell
Show All
- Source
- Cite
- Save
Citations (5)
Real-world data from a Molecular Tumor Board: improved outcomes in gynecologic and breast cancer patients with precision medicine

2021 Gynecologic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Durvalumab With Olaparib and Paclitaxel for High-Risk HER2-Negative Stage II/III Breast Cancer: Results From the Adaptively Randomized I-SPY2 Platform Trial

2020
Show All
- Source
- Cite
- Save
Citations (0)